Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)

NCT01127646 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01127646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01127646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Terminated
Start date
June 30, 2010
Completion date
May 31, 2011
Enrollment
23 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder